Regulation of Vascular Endothelial Growth Factor in endometrial cancer cells by food compounds by Dann, James MacBeth
REGULATION OF VASCULAR ENDOTHELIAL 
GROWTH FACTOR IN ENDOMETRIAL CANCER 
CELLS BY FOOD COMPOUNDS
JAMES DANN
A thesis submitted in partial fulfilment of the requirements for the 
Degree of Master of Science in Cellular and Molecular Biology at the 
University of Canterbury 
June 2008
1
TABLE OF CONTENTS
ACKNOWLEDGEMENTS 5
ABSTRACT 6
ABBREVIATIONS 8
INTRODUCTION 10
1.1 Endometrial Cancer 10
1.1.1 Incidence & Epidemiology 10
1.1.3 Prognosis 12
1.2 Hypoxia and Angiogenesis 13
1.2.1 Hypoxia 13
1.2.2 Angiogenesis 14
1.3 Molecular responses to hypoxia 16
1.3.1 HIF-1 α and β 16
1.3.2 Vascular Endothelial Growth Factor (VEGF) 17
1.3.3 HIF1-α, VEGF and Endometrial Cancer 19
1.4 Food and Cancer 21
1.4.1 Resveratrol 22
1.4.2 EGCG 23
1.4.3 Aims of this study 25
MATERIALS AND METHODS 26
2.1 Materials, solutions and media 26
2
2.2 Preparation of Primary Culture 26
2.2.1 Collection of Endometrial Tumour Samples 26
2.2.2 Cell Dispersion 26
Maintenance of Cell Culture 28
Splitting Confluent Cell Culture 28
Thawing Cells 30
Stimulation of Cell Culture 31
2.3 ASSAYS 32
2.3.1 MTT Viability Assay 32
2.3.2 Protein Assay 32
2.3.3 VEGF ELISA 33
RESULTS 37
3.1 Effects of Cobalt Chloride on VEGF Secretion in endometrial 
cancer cells 37
3.1.1 Effect of Duration of CoCl2 Treatment on VEGF Release from RL952 
cells 38
3.1.2 Effect of concentration of CoCl2 exposure on VEGF release from  
RL952 Cells 39
3.1.3 Effect of CoCl2 concentration on VEGF release from Endometrial 
Cancer Cells 41
3.2 Effects of Resveratrol on VEGF Release from in Endometrial 
Cancer Cells 45
3.2.1 Effects of Resveratrol Concentration on Cell Viability 45
3.2.2 Effects of Resveratrol in combination with CoCl2 on cell viability 47
3.2.3 Effects of Resveratrol on VEGF Levels 49
RL952 Endometrial Cell Line 49
Primary endometrial tumour cells 51
3
3.3 Effect of EGCG on VEGF release from in endometrial cancer 
cells 54
3.3.1 Effect of EGCG on VEGF Levels 54
3.4 Immunohistochemistry 57
DISCUSSION 58
4.1 Effect of CoCl2 on VEGF release from endometrial cancer cells
 58
4.2 Effect of Resveratrol on VEGF release from endometrial 
cancer cells 59
4.3 Effect of EGCG on VEGF release from endometrial cancer 
cells 61
4.4 Suggestions for further research 62
REFERENCES 65
APPENDICES 73
SOLUTIONS 73
Cell Culture 73
Experimental Treatments 76
ELISA Reagents 77
4
ACKNOWLEDGEMENTS
I would like to thank my supervisor, Associate Professor John Evans, for all his 
supervision with my experimental work, feedback on my writing, and 
development of ideas in the course of this project. Many thanks also my associate 
supervisors, Dr Drusilla Mason, for her help with guiding me in the right 
direction, and Dr Peter Sykes for his invaluable support and opinion, as well as 
helping to provide the endometrial cancer samples that are such a key part of the 
study. I would also like to thank Dianne Harker from the Department of Obstetrics 
and Gynaecology, Christchurch Women’s Hospital, for helping with processing 
and logging the samples. Helen Morrin from the Cancer Society Tissue Bank
Thanks must also be given to Junko Nagase, as without her assistance in showing 
me how to perform many of the laboratory methods necessary for the project, I 
would have had a more difficult time. The assistance of two Dutch students who 
worked in our lab, Ilona Molenaar and Gaby  Posthumus, was a great help in 
working on much of the cell culture. I would also like to think Katya Volkova and 
Michelle Hunt, from the Angiogenesis Research Group at the University of Otago, 
Christchurch, for their assistance and advice on laboratory techniques. 
Finally, I would like to thank Gloria Evans for her coffee, baking, company, and 
motherly advice around the lab. 
5
ABSTRACT
Endometrial cancer is one of the most significant gynaecological malignancies 
that affect women from New Zealand and the rest of the world. One of the critical 
stages in the development of a tumour is the onset of hypoxia.  The malignancy 
responds by having raised levels of Hypoxia Inducible Factor (HIF) that in turn 
induces increased production of Vascular Endothelial Growth Factor (VEGF). 
VEGF is a potent angiogenic factor that will mediate vascular supply of nutrients 
and oxygen to the developing tumour. The aim of this study was to investigate 
whether two compounds found in extracts of plant  materials, Resveratrol 
(Resveratrol) and Epigallocatechin gallate (EGCG), altered the levels of VEGF in 
the supernatant of cultured endometrial cancer cells. 
 Resveratrol is a phytoalexin that is found in many foods, such as grapes, 
nuts and berries, as well as in high concentrations in some red wines. 100 µM of 
resveratrol was added to cell cultures for 24 hours. VEGF levels in the supernatant 
were then analysed using ELISA. Resveratrol was found to have significant 
inhibitory effects in both primary endometrial cancer cell cultures and 
immortalised endometrial cancer cell cultures. Resveratrol was also shown to 
reverse the increase in VEGF caused by the hypoxia mimic cobalt  chloride 
(CoCl2). 
 Epigallocatechin gallate (EGCG) is an antioxidant  catechin extracted 
from green tea. The effect of EGCG was analysed using the same method as for 
resveratrol. 100 µM of EGCG was also shown to have a significant inhibitory 
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effect on the level of VEGF in the supernatant of cultured endometrial cancer 
cells, as well as reducing the effect of CoCl2.
 These results suggest  that selected food compounds, resveratrol and 
EGCG, can reduce VEGF levels by inhibiting HIF. Further investigation This may 
have anti-tumour effects in women with endometrial cancer.
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ABBREVIATIONS
ARNT   aryl hydrocarbon receptor nuclear translocator protein
BCA   bicinchoninic acid
BMI   body mass index
BSA   bovine serum albumin
CoCl2   cobalt chloride
DMSO    dimethyl sulfoxide
EGCG   (-)-epigallocatechin-3-gallate 
ELISA    enzyme linked immunosorbent assay
FBS   fetal bovine serum
FIGO   Federation Internationale de Gynecologie et d’Obstetrique
HIF   hypoxia inducible factor
HRP   horse radish peroxidase
MEM   minimum essential medium
MTT    3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
MVD   microvessel density
NS   not significant
PBS   phosphate buffered saline
PHD   prolyl hydroxylase
PRF-MEM  phenol red free minimal essential medium
RIPA   radioimmuno precipitation assay
RT-PCR   real-time polymerase chain reaction
8
si-RNA   small interfering ribonucleic acid
TMB+   tetramethylbenzidine
VEGF   vascular endothelial growth factor
VEGFR   vascular endothelial growth factor receptor
VHL   von-Hippel Lindau
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1INTRODUCTION
1.1 Endometrial Cancer
Endometrial cancer is the cancer found in the endometrium, the lining of the 
uterus.  It is one of the most common cancers occurring in women (Bakkum-
Gamez et al., 2008). The incidence and mortality rates for this disease are 
increasing in the western world. Treatment for endometrial cancer, though 
invasive, is very  effective for most women. However, recurrent endometrial 
cancer is very difficult to treat, and survival rates for these patients are very  low. 
Hence, a non-invasive, non-toxic treatment remains a clinical need.
1.1.1 Incidence & Epidemiology
Endometrial cancer is the most common invasive tumour of the female genital 
tract (Ozbudak et  al., 2008). Epidemiological studies show that the incidence of 
the disease is increasing. Understanding the controlling factors is key to 
successful treatment and intervention in patients with endometrial cancer.
There are a number of significant risk factors for endometrial cancer, which 
contribute to the increase in incidence in western countries. Obesity is a very 
strong risk factor for endometrial cancer. Women with a Body  Mass Index (BMI) 
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of over 25 kg.m2 have twice the risk of developing the disease; for women with a 
BMI of over 30 kg.m2, the risk is triple. As obesity  is widely acknowledged to be 
an epidemic in western countries, the rate of endometrial cancer in these countries 
is forecast to increase further. For a further comparison, the rate of endometrial 
cancer in the US, where around 40% of adult women are obese, is 7 times that in 
Japan, where 3% of adult  women are obese. A link has also been established 
between the excessive consumption of fat, and an increase in the rate of 
endometrial cancer. One of the most marked risk factors is post-menopausal 
status. Approximately  75% of endometrial cancers are identified in post-
menopausal women. With an aging populating, the number of post-menopausal 
women in society will also increase, and with it, the rates of endometrial cancer. 
Breast cancer has also been linked to increased rates of endometrial cancer. This 
may be in part due to shared risk factors for the two diseases. However, it  has also 
been noted that Tamoxifen, a drug frequently used in treatment of breast cancer, is 
linked to an increased incidence of endometrial cancer (Pukkala et al., 2002). 
Without  an effective treatment for endometrial cancer, dietary and demographic 
pressures will ensure that the incidence of this disease continues to increase 
(Wright et al., 2007). 
In New Zealand endometrial cancer is the 6th most common cancer in women, 
with an incidence of 15 cases per 100,000 women per year. This is predicted to 
increase as the population of New Zealand ages, and becomes more obese. 
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Endometrial cancer is more prevalent in the New Zealand Maori population than 
in the New Zealand non-Maori population. This reflects socio-economic status as 
well as genetics. Mortality is also higher within this population. 
1.1.3 Prognosis
Prognosis for women with endometrial cancer is largely dependent on the stage of 
the disease when it is first  diagnosed. If detected early, removal of the uterus will 
remove both the cancer and the risk for most patients. A total abdominal 
hysterectomy (surgical removal of the uterus) with removal of both ovaries 
(bilateral salpingo-oophorectomy) is the most  common therapeutic approach 
(Bakkum-Gamez et al., 2008). The chances of a patient’s survival are correlated 
with the stage of the cancer. The International Federation for Gynaecology  and 
Obstetrics (FIGO) classification system rates endometrial cancers from stage I 
(least progressed) to stage IV (highly progressed). The 5-year survival rate for 
women with stage 1 endometrial cancer is between 75% and 95%, while for 
women with stage 4 tumours a less than 5% chance of 5-year survival. 
There is a small group  of patients who will have recurrent cancer. As the surgical 
approach can only be undertaken once, treating patients with systemic 
endometrial cancer becomes problematic. Chemotherapy is not ideal, as it has a 
low chance of success, coupled with a high level of toxicity (Oehler et  al., 2005). 
Hypoxia has been shown to be a significant contributor to the development of 
recurrent endometrial cancers (Pijnenborg et al., 2007).
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1.2 Hypoxia and Angiogenesis
1.2.1 Hypoxia
Hypoxia occurs when the oxygen tension within a tissue becomes low.  Cells 
require constant access to the vasculature which provides nutrients and oxygen. If 
access to the vasculature becomes restricted, then the tissue can only  acquire 
limited amounts of oxygen and nutrients. Thus, hypoxia limits the ability of cells 
to grow. Tissue hypoxia is a characteristic of most rapidly developing tumours.
The oxygen tension in normal tissue is approximately  7%. Hypoxia is generally 
associated with oxygen tension dropping below 5% (Gordan and Simon, 2007). 
The average oxygen tension of tumours is 1.5% (Kimbro and Simons, 2006; 
Vaupel, 2004; Vaupel et  al., 2001).  As the cells cannot survive with oxygen levels 
as low as this, hypoxic tumours can respond with either programmed cell death 
(apoptosis) or the development of new vasculature (angiogenesis). While much 
research is conducted into apoptosis,the study reported in this thesis is concerned 
only with angiogenesis. 
Hypoxia is a common feature of solid tumours, frequently occurring in the cells of 
developing tumours (Melillo, 2006). As cancerous cells grow without the cellular 
controls of normal tissues, tumours lack the cellular architecture of normal tissues 
(Garcia, 2006). While cells on the outer extremities of a growing tumour can 
exchange oxygen and nutrients with cells in close proximity, the cells at the centre 
of the tumour will lack this possibility. Blood vessels are required to carry 
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nutrients and oxygen to these cells. They are also needed to remove waste 
products from the cell. Thus, without blood vessels, the core of a tumour can 
become necrotic. Without the development of new vasculature the growth of a 
tumour will be self-limiting. Angiogenesis is the process by which tumours 
develop new vasculature, thus promoting the transition from limited to rapid 
growth in tumours (Wong et al., 2003).
1.2.2 Angiogenesis
Angiogenesis is the process by which cells develop new blood vessels. This 
occurs normally in growing tissues, as well as in tissues that  are repairing any 
damage to blood vessels caused by a wound. It also occurs routinely as part of a 
woman’s menstrual cycle, but is uncommon in normal adult tissue. The process is 
utilised by  tumour cells to provide the vasculature required for continued cell 
growth. As angiogenesis is a critical stage in the development of cancers it is a 
subject of much interest.
Though angiogenesis is linked with the growth of cancers it  is a process that 
occurs normally in growth and wound healing.  Synthesis of new blood vessels 
begins when endothelial cells, which line the walls of existing blood vessels, 
receive a stimulus to create new vessels. This signal includes the common growth 
factor, Vascular Endothelial Growth Factor (VEGF). On receiving this signal the 
endothelial cells release protease enzymes, which break down the surrounding 
extracellular matrix. Endothelial cells then migrate to and proliferate in the newly 
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created space within the extracellular matrix. As this process continues, several 
millimetres of new blood vessels can be created per day. 
Unlike most other mature tissues, angiogenesis is part of the normal physiological 
process in the endometrium. Once the endometrial lining is shed as part of the 
menstrual cycle, angiogenesis is required to grow a new endometrium, ready  for 
implantation. As the menstrual cycle repeats monthly, the endometrium is almost 
always undergoing angiogenesis, and hence the control of angiogenesis in 
endometrial cancers may differ from that in other tumour tissues. Because of this 
the role of angiogenesis in endometrial cancer is of particular interest. 
When a tumour reaches a size where it becomes hypoxic (see previous section) it 
then needs to create new blood vessels. Tumours can trigger an angiogenic 
response to achieve this. With new blood vessels, the central cells of the tumour 
can be prevented from becoming necrotic, and the tumour can continue growth. 
The microvessel density (MVD) of a tumour, which reflects the size and number 
of blood vessels in the tumour, is a marker of angiogenesis. Without angiogenesis 
the tumour would only  be able to grow to a small size, and it has been shown that 
increased angiogenesis is linked to poor prognosis in women with endometrial 
cancer (Sivridis, 2001). Hence preventing tumour angiogenesis is the focus of 
much research and drug development. One of the key molecules of the hypoxic 
response leading to angiogenesis is Hypoxia Inducible Factor (HIF), which will 
be discussed in the next section. 
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1.3 Molecular responses to hypoxia
1.3.1 HIF-1 α and β
Hypoxia Inducible Factor 1 alpha (HIF1-α) is a transcription factor that  has a 
critical role in mediating the hypoxic response. It is a heterodimeric molecule, 
consisting of an α and β subunit. HIF1-α binds to a specific gene sequence, 
leading to the expression of target genes. Because of the key  role it  plays in 
mediating the response to hypoxia, HIF1-α is a target of much interest for agents 
that may inhibit it. As direct measurement of tumour oxygen levels is 
difficult ,HIF1-α is often used as a marker of tumour hypoxia (Vaupel and Mayer, 
2007).
The molecule was first identified as a regulator of erythropoietin expression in 
response to low oxygen. It  is part of the helix-loop-helix family of transcription 
factors. HIF1-α is coded by  a 15 exon gene, the product of which is a 120-kD 
HIF1-α subunit that complexes with a 91 to 94 kD HIF1-β subunit to form the 
active heterodimer (Iyer et al., 1998). While it requires two subunits to be active, 
the α subunit is of most interest. HIF1-β is a constitutively expressed protein 
(Stroka et al., 2001),  also known as ARNT - Aryl Hydrocarbon Receptor Nuclear 
Translocator protein (Wang et al., 1995). The expression of HIF1-β is not  affected 
by the amount of cellular oxygen. The protein is found mainly  in the nucleus of 
the cell.
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Although HIF1-α is transcribed by the cell at a constant rate, the stability of HIF1-
α is dependent on oxygen availability. Under normoxic conditions, it is readily 
degraded. Two proline residues are hydroxylated by a family of oxygen-dependent 
Proline Hydroxylases (PHD1-3) Bruick and McKnight, 2001; Jaakkola et al., 
2001). This leads to the hydroxylated HIF1-α being bound to and ubiquitinylated 
by the von Hippel-Lindau (VHL) tumour suppressor (Cockman et al., 2000; 
Epstein et al., 2001; Maxwell et al., 1999; Yu et al., 2001a, b). When the cell is 
hypoxic, hydroxylation by the PHD enzymes is reduced, leading to an increase in 
the amount of HIF1-α present in the cytoplasm. Stable HIF1-α then translocates to 
the nucleus, where it  forms a heterodimer with HIF1-β. The active HIF1 dimer 
can then bind to, and induce transcription, of target genes. (Kong et al., 2005). 
More than 100 HIF1-α target genes have been identified. One of the genes which 
HIF1-α binds to encodes Vascular Endothelial Growth Factor (VEGF) (see next 
section). 
1.3.2 Vascular Endothelial Growth Factor (VEGF)
Vascular Endothelial Growth Factor (VEGF) is a potent angiogenic factor and one 
of the primary  effectors of hypoxia (Wong et al., 2003). It is a 40 - 45 kDa 
disulphide linked homodimeric glycoprotein, responsible for the recruitment of 
proteases and endothelial cells that  begin growing new blood vessels (Ozbudak et 
al., 2008). Expression of VEGF is stimulated by HIF (see previous section). 
VEGF is secreted by endothelial cells, and acts by binding to the VEGF receptor. 
Measurement of VEGF levels in the supernatant of cells cultured in vitro can be 
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quantified using the ELISA assay, This shows the effects of various treatment 
conditions on the level of VEGF.
As mentioned previously, VEGF is a key molecule in the angiogenic process. 
Once its production has been stimulated by hypoxia, as well as by  other growth 
factors, cytokines, or oncogenes, VEGF leads the recruitment of proteases to the 
site where the new blood vessel is required (Ozbudak et al., 2008). VEGF binds to 
and activates Vascular Endothelial Growth Factor Receptor (VEGFR), which is a 
tyrosine kinase transmembrane protein that specifically binds VEGF (Meunier-
Carpentier et al., 2005; Yokoyama et al., 2003). The activation of VEGFR induces 
a signal within the cell, leading to the release of proteases. These proteases 
enzymatically break down the extracellular matrix, allowing for endothelial cells 
to migrate into the space and create new vessels. 
While VEGF has been shown to have a key  role in tumour angiogenesis, it is also 
involved in angiogenesis of the normoxic endometrium. It is essential for the 
cyclic growth of the endometrium, which requires the growth of new vasculature 
each time the endometrium is replaced. Studies have also shown that  VEGF is 
required for successful implantation of the ovum (Hastings et al., 2003; Rockwell 
et al., 2002).
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1.3.3 HIF1-α, VEGF and Endometrial Cancer
Hypoxia, HIF1-α and VEGF are all strongly implicated in endometrial cancer. 
Elevated levels of HIF1-α, as well as mutations in the gene which codes for the 
transcription factor, have been shown to be increased risk factors for cancer 
(Zhong et al., 1999). As increased HIF1-α leads to increased VEGF, elevated 
levels of VEGF would be expected to occur with greater prevalence in patients 
with cancer. Studies in a number of cancer types have shown this to be the case. 
Such studies have also shown that there is a significant  correlation between 
HIF1-α levels and VEGF levels. 
Elevated HIF1-α levels have been shown in the cells of many types of cancer 
(Kimbro and Simons, 2006). Breast cancer is one example where the over-
expression of HIF1-α is strongly  correlated with the disease (Alkhalaf et al., 2008; 
Zhong et al., 1999). High levels of HIF1-α at  diagnosis have been shown to be an 
accurate predictor for early relapses and metastatic disease in breast cancer 
patients (Dales et al., 2005). As HIF1-α is elevated in these examples, we would 
expect VEGF to also be raised. Studies have shown that there is a strong 
correlation between HIF1-α expression and VEGF levels (Wong et al., 2003). In 
transgenic mice, designed to over-express the HIF1-α gene in skin and squamous 
epithelial cells, researchers found that there was a 13-fold elevation in the levels 
of VEGF expressed (Elson et al., 2001).
As both HIF1-α and VEGF are molecules which have important roles in the 
hypoxic response, they have also been shown to have important roles in human 
cancers (Melillo, 2007). Elevated levels of the two molecules may indicate a 
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disease state. A number of studies have shown that HIF1-α, VEGF, or both, are 
important in endometrial cancer. A DNA microarray analysis showed that the level 
of HIF1-α gene expression was higher in the endometrial cells of cancer patients 
than in the equivalent cells from a non-cancer control. The up-regulation of HIF1-
α has been shown to be a common event in endometrial cancers (Sivridis et al., 
2002). A more recent study  has shown that HIF1-α expression was observed in 
73% of the primary tumours of patients with endometrial carcinoma. (Pijnenborg 
et al., 2007) In a study which analysed endometrial cancers by grade, 90% of 
stage III + IV tumours showed high expression of VEGF, while 100% of that 
group showed high HIF1-α levels (Ozbudak et al., 2008). Associations have been 
shown between mutations in the HIF1-α gene and endometrial cancer. An 
epidemiological study in Turkish women showed that HIF1-α mutations were a 
significant risk factor for endometrial cancer. High MVD has been shown to be 
associated with HIF1-α gene mutations in endometrial cancer (Horree et al., 
2008), as well as being a risk factor for the recurrence of the disease (Pijnenborg 
et al., 2007)
Clinical studies have shown that VEGF can be an important predictor of 
endometrial carcinoma. The level of VEGF can be used as independent prognostic 
factor for women with stage I endometrial cancer ((Pijnenborg et al., 2007), A 
combination of histological grade and VEGF expression can also be used as 
independent predictors of clinical outcome (Chen et al., 2001). However, some 
studies have failed to find a link between VEGF and prognosis. In a study of 
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Finnish women, no significant correlation was seen between VEGF expression 
and the rate of survival of patients with endometrial cancer. Also, while HIF1-α is 
strongly linked to the disease, it’s expression has not been shown to correlate with 
tumour grade, stage, or myometrial invasion.
1.4 Food and Cancer
It has been shown that  populations in some countries have significantly lower 
levels of diseases, including heart disease and cancer, and been it has 
hypothesised that these differences may in part be due to the diets in these 
countries. One such observation is called the “French Paradox”, where the 
population of France has significantly  lower levels of a range of medical 
conditions, including cardiovascular disease and cancer, despite a diet that is 
richer in fats and alcohol than most other Western nations. It has been 
hypothesised that this may be an effect of the French diet, which includes a high 
amount of oils such as olive oil, as well as regular consumption of red wine. As 
red wine is fermented with the skin of the grape, unlike most white wine where 
the skins are separated, red wine contains a higher concentration of phenols and 
flavonoids that may be linked to health benefits seen in epidemiological studies 
(Saiko et al., 2008). 
The North East Asian region also has a population with lower than expected rates 
of cancer and cardiovascular diseases. Japan in particular has a population with 
significantly lower rates of cancer than would be expected from a nation that 
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consumes large amounts of protein and is relatively sedentary. Again, this may be 
in part attributable to consumption of relatively  large amounts of omega-3 rich 
fish oil, as well as regular consumption of green tea. During processing of green 
tea, most of the green leaf phenols remain unoxidised (unlike black tea). Hence 
extracts of green tea include polyphenols. One such polyphenol is (-)-
epigallocatechin-3-gallate (EGCG). The beneficial effects of green tea and its 
active components have been documented in the literature and include cancer 
chemoprevention, inhibition of tumour cell growth, invasion, and metastasis, and 
antiviral and anti-inflammatory activities.
 
1.4.1 Resveratrol
Resveratrol (3,4’,5-trihydroxystilbene) is a potential anti-angiogenic molecule that 
is found in significant concentrations in red wine (Baur and Sinclair, 2006). It was 
first isolated in 1940 (Takaoka, 1940), but investigations into the potential utility 
of the substance as a nutraceutical were increased after it was identified at  high 
concentrations in red wine in 1992 (Siemann and Creasy, 1992). In 1997 
resveratrol was shown to have dramatic anti-carcinogenic effects in mice, Jang et 
al., 1997) and subsequent studies have supported the notion that resveratrol has 
chemoprotective activities ((Bhat and Pezzuto, 2002). It has also been shown to 
have anti-inflammatory, neuroprotective and antiviral properties (Bhat and 
Pezzuto, 2001). It  is not  yet known whether resveratrol has any effect at 
concentrations found in a normal human diet. 
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While resveratrol has been shown to have marked effects in vivo, it’s action is not 
clearly  understood (de la Lastra and Villegas, 2007). It has been demonstrated to 
have chemoprotective activities in each of the three stages of cancer - initiation, 
promotion and progression (Athar et al., 2007). It has been shown that  resveratrol 
enhances the degradation of HIF1-α protein, although exact mechanisms have not 
yet been elucidated. Resveratrol also inhibits the accumulation of HIF1-α protein, 
which leads to a reduction of VEGF transcriptional activity. We have chosen to 
study resveratrol in this project  because in the few studies that investigated HIF1-
α, it was reported that resveratrol efficiently blocked HIF1-α and VEGF 
expression in ovarian cancer cells (Park et al., 2007), human papillomavirus-
transfected cervical cancer cells (Tang et al., 2007), human tongue squamous cell 
carcinoma and hepatoma cells (Zhang et al., 2005). Given the efficient inhibition 
of HIF1-α and VEGF seen in these few studies we hypothesise that resveratrol 
will also inhibit VEGF in endometrial cancer cells.
1.4.2 EGCG
EGCG is a catechin that is found in green tea Camellia sinensis (Yance 2006). It 
has recently be shown that EGCG can have a wide range of health benefits. At the 
cellular level, it  has been shown that EGCG interferes with HIF1-α expression. A 
prospective cohort study  from Saitama Prefecture, Japan reported that green tea is 
preventative against cancers in many organs including stomach, lung, colorectum 
and liver (Imai et al., 1997). Another cohort study (Iowa Women’s Health Study) 
23
found that food-derived catechin intake was inversely associated with rectal 
cancer incidence in postmenopausal women (Arts et al., 2002). 
Both in vitro and in vivo studies have shown that EGCG has antiangiogenic 
properties (Jung and Ellis, 2001). The substance has been shown to inhibit 
angiogenesis and restrain growth in tumour models (Fassina et al., 2004). 
Evidence of the mechanisms of EGCG action is incomplete, however it has been 
shown to reduce levels of VEGF by  decreasing mRNA levels (Sartippour et al., 
2002), inhibiting gene expression (Zhang et al., 2006) and decreasing the levels of 
VEGF secreted (Sartippour et al. 2002). HIF1-α protein accumulation is inhibited 
in the presence of EGCG (Zhang et al., 2006).
Although the mechanisms through which EGCG reduces angiogenesis are not 
completely elucidated, evidence of the potential health benefits have led to the 
introduction of a strategy of cancer prevention with green tea in Japan (Fujiki, 
2005).  Drinking green tea has been reported to be protective against  oesophageal 
cancer (Gao et al., 1994), colorectal cancers in females from Hebei Province, 
China (Zhang et al., 2002), stomach cancers in Nagoya, Japan (Inoue et al., 1998), 
gastric cancer in Kyushu, Japan (Kono et  al., 1988), pancreatic and colorectal 
cancers in Shanghai, China (Ji et  al., 1997) and breast cancer in Saitama, Japan 
(Nakachi et al., 1998). The success of these trials encourages the investigation of 
the effect of EGCG on the regulation of VEGF secretion by endometrial cancer 
cells.
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1.4.3 Aims of this study
As hypoxia causes an increase in VEGF in cells, which leads to angiogenesis in 
developing tumours, it  is important to investigate whether an inhibition of HIF1-α 
can reduce the levels of VEGF in endometrial cancer cells, and prevent tumour 
development. 
The overall aim of this project was to investigate whether increases in VEGF 
secretion from cultured endometrial cancers could be inhibited by naturally 
occurring compounds. Specifically, the first  objective was to investigate whether 
CoCl2, a hypoxia mimic reported to increase levels of HIF1-α, elicits an increase 
in VEGF secretion from endometrial cancer cells. The second objective was to 
observe whether the secretion of VEGF in basal culture conditions in vitro, could 
be reduced or prevented by treating the cells with the food compounds, resveratrol 
and EGCG. The third aim of this study was to investigate whether the CoCl2 
stimulated increase in VEGF could be reversed by the addition of resveratrol and 
EGCG.
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2MATERIALS AND METHODS
2.1 Materials, solutions and media
For details of materials used in this study, see Appendix A
For details of media and solutions used in this study, see Appendix B
2.2 Preparation of Primary Culture
2.2.1 Collection of Endometrial Tumour Samples
Endometrial cancer tissue samples were collected from consenting women (under 
Ethics Approval CTB/04/02/005) with endometrial cancer undergoing 
hysterectomy operation to removed the uterus. A sample of the tumour was 
removed by the duty pathologist, and placed in cell culture media in preparation 
for dispersion.
2.2.2 Cell Dispersion
All cell culture work was undertaken in a sterile biological safety  cabinet 
(EMAIL Air Handling Biological Safety  Cabinet Class II), unless otherwise 
indicated. All glassware, solutions and instruments used for cell preparation were 
sterilised by autoclaving or 70% ethanol spray before use.  Tumour tissue was 
washed briefly  three times in α-MEM  pre-warmed to 37°C. After washing, the 
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tissue was placed onto a glass slide, where it was minced into small pieces (less 
than 3 mm3) using a size 24 surgical blade. The minced tissue was transferred into 
a 15 ml Falcon tube, and 10 ml of α-MEM were added. It was then centrifuged at 
1500 rpm (Centrifuge 5702, Eppendorf, Germany) for 5 minutes at room 
temperature. The supernatant was removed by aspiration with a Pasteur pipette. 
The tissue pellet was then resuspended in 10 ml of α-MEM, and centrifuged as 
before. The supernatant was removed by  aspiration as before The tissue pellet was 
then resuspended in 4 ml of collagenase solution. and placed into an incubator 
(Forma Scientific) at 37ºC with 5% Co2 for 30-45 minutes. The tube was shaken 
manually at ten-minute intervals. 
The cells were then mechanically disrupted using an 18-gauge needle to triturate 
the solution repeatedly. Next, the suspension was centrifuged for 5 minutes at 
1500 rpm. The supernatant was removed by aspiration, and the pellet was washed 
by resuspension in α-MEM, followed by centrifugation for 5 minutes at 1500 rpm. 
The supernatant was removed, and centrifuged as above. The supernatant was 
removed by  aspiration. Pellet was then resuspended in α-MEM. The resuspended 
cells were then passed through a 70 µm filter. The filtrate was collected and 
centrifuged as above. The cells were then resuspended in α-MEM supplemented 
with 10% Fetal Bovine Serum (α-MEM  with FBS; see appendix B), and plated 
into a 25 cm2 flask. 
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Maintenance of Cell Culture
Cell culture media was changed when required, which was generally every second 
or third day. Medium was aspirated and α-MEM with FBS, which had been pre-
warmed to 37°C, was then added to the flask, using a 10 ml transfer pipette. The 
volume of α-MEM with FBS added was dependent on the size of the flask: 25 cm2 
– 10 ml; 75 cm2 – 20 ml; 175 cm2 – 30 ml
Splitting Confluent Cell Culture
When cells reached a confluent state, they were split in preparation for further 
use. Confluence of cells was determined by observing the flask under the confocal 
microscope (Olympus CK40). Once the cultures had become confluent the cell 
culture medium was removed by aspiration. 10 ml of Phosphate Buffered Saline ,
(PBS; see Appendix B) pre-warmed to 37°C, was then used to wash the cells. This 
PBS was removed, and the wash step was repeated twice more. Following the 
final aspiration of the PBS from the flask, 2.5% trypsin in PBS was added to the 
cells, with the volume of trypsin added dependent on the size of the flask: 25 cm2 
flask – 0.5 ml; 75 cm2 flask – 1 ml; 175 cm2 flask – 2 ml. Cells were dislodged by 
light tapping on the side of the flask. Split cells were used for four purposes:
I. Transfer into a larger sized flask for further growth
10 ml of α-MEM with FBS was added to the flask with the cells in trypsin. The 
cells were then resuspended in the α-MEM with FBS, and transferred into a sterile 
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flask. Further α-MEM with FBS was then added to bring the total volume of 
medium in each flask to 20 ml (for 75 cm2 flask) or 30 ml (175 cm2 flask). 
II. Transfer into a multi-welled plate for an experiment
10 ml of α-MEM  with FBS was added to the cell suspension in the flask, and the 
cells and media were then transferred into a 15 ml Falcon tube. Cells were evenly 
dispersed through the media by light tapping on the outside of the tube. A small 
sample of the cell suspension was then removed, and used to perform a cell count 
with a haemocytometer. Cells were then centrifuged at 1500 rpm for 5 minutes at 
room temperature and the supernatant was aspirated. α-MEM with FBS was then 
added, with the volume added dependent on the cell count performed earlier, and 
the concentration of cells required. 0.5 ml of cell suspension was added to each 
well of a 24 well plate. Cells were plated at a concentration of 2.4x105 cells/ml, 
giving approximately 120,000 cells per well in each well of a 24 well plate. 
III. Frozen for storage
10 ml of α-MEM  with FBS was added to the cell suspension in the flask, and the 
cells and media were then transferred into a 15 ml Falcon tube. Cells were evenly 
dispersed through the media by light tapping on the outside of the tube. A small 
sample of the cell suspension was then removed, and used to perform a cell count 
with a haemocytometer. Cells were then centrifuged at 1500 rpm for 5 minutes at 
room temperature. The tube was brought back to the culture hood, and the 
supernatant was aspirated. α-MEM with FBS was then added, to give a final 
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concentration of 2x106 cells per ml. To each cryovial, 400 µl of FBS, 100 µl of 
DMSO, and 500 µl of the cell suspension was added. The cryovial was then 
placed into a Mr Frosty container, and stored at -80ºC for 24 hours. Vials are then 
removed from Mr Frosty and placed into a labelled box in the -80ºC freezer until 
required.
IV. Fixed for histological staining
10 ml of α-MEM  with FBS was added to the cell suspension in the flask, and the 
cells and media were then transferred into a 15 ml Falcon tube. Cells were then 
centrifuged at 1500 rpm for 5 minutes at room temperature. The supernatant was 
then removed by aspiration. The cell pellet was then resuspended in 10 ml of 
fixative solution and passed on to the pathology department who fixed the cells, 
then stained them with the required immunologic stains. 
Thawing Cells
For culturing, vials were removed from the freezer and thawed at room 
temperature. Next, they were transferred into a 25 cm2 flask containing 10 ml of 
pre-warmed α-MEM with FBS using a sterile 1 ml pipette. Cells were then 
incubated overnight, and the medium was replaced with fresh α-MEM with FBS 
the following day.
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Stimulation of Cell Culture
Once confluent, cells grown in Phenol-Red Free Minimum Essential Medium 
(PRF-MEM; see Appendix B) for 24 hours. Each of the wells of a 24 well plate 
contained 500 µl of PRF-MEM. After being incubated for 24 hours, the medium 
was removed by  aspiration and 500 µl of fresh PRF-MEM was added to each 
well. Plates were then incubated for a further 1 hour. Following this incubation, 
the medium was then aspirated and replaced with 500 µl of the treatment solution 
for stimulation. The plate was then returned to the incubator for the course of the 
experiment (24 hours unless otherwise specified).
Experimental treatments were prepared in the biological safety cabinet  to give the 
concentrations required for the various experiments detailed in the results section. 
Appropriate volumes of PRF-MEM were measured out into Falcon tubes or 1.7 
ml Eppendorf tubes, dependent on the total volume required. Tubes were then 
made up to the required total volume with the appropriate treatment solutions. The 
details of the different concentrations and treatment regimes used in the individual 
experiments can be found in the following ‘Results’ chapter. Finally, the tubes 
were inverted repeatedly to mix before being used in the experiments.
On the completion of the experimental incubation the supernatants were collected 
from the plate. 500 µl of supernatant from each well was placed in an individually 
labelled 0.5 ml or 1.7 ml Eppendorf tube. These were then stored in the freezer 
until required for assay. 
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2.3 ASSAYS
2.3.1 MTT Viability Assay
3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium (MTT) tests were 
performed as a measure of cell viability  and cell proliferation after cells had been 
exposed to experimental treatment solutions. After the supernatants have been 
removed and stored, as above, each well of the plate was washed with PBS. 500 
µl of PBS was added to each well, then removed by aspiration. This wash step 
was then repeated. 900 µl of PRF-MEM  was then added to each well of the plate. 
Next, 100 µl of MTT (5 ng/ml) was added, and the plate was placed in the 37ºC 
incubator for 2 hours for the colour to develop. 
Following the incubation, 1 ml of 10% DMSO in isopropanol was added to each 
well. Crystals produced during the incubation were then dislodged from the plate 
using a pipette. The contents of each well was transferred into an Eppendorf tube 
and then centrifuged for 5 minutes at 10,000 rpm. An aliquot of the supernatant 
from each tube was next transferred into a 96-well plate. Absorbance was 
measured at 570 nm (wavelength reduction at 690 nm), using water as a blank.
2.3.2 Protein Assay
Protein assay  experiments were performed using the bicinchoninic acid (BCA) 
protein assay kit from Pierce Biotechnology. This kit contains the working reagent 
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and albumin standards used in the assay. 100 µl of RIPA Lysis buffer was added to 
each well on the plate. Cells with RIPA were left for ~10 minutes for lysis to 
occur. 900 µl 1X PBS was added to each well, bringing the total volume of 
solution in each well to 1 ml. 150 µl of this diluted protein solution was then 
transferred in duplicate to a 96-well plate. A standard curve was created by adding 
8 albumin standards in duplicate. The range of standards was created by serial 
dilution from a high concentration of 200g/ml, down to 0g/ml. 150 µl of working 
reagent was added to each of the sample and standard wells on the plate. The plate 
was then covered, and incubated at 37ºC for two hours.  Following incubation, the 
plate was then left to cool to room temperature. Finally, the absorbance of each 
well was measured at 562 nm using a plate reader.
2.3.3 VEGF ELISA
Solutions
ELISA was performed according to the methods described in the R&D Systems 
DuoSet ELISA Development System kit. The kit contains:
Capture antibody
Detection antibody
Streptavidin / HRP
VEGF Standard
Reagents also required:
Reagent Diluent (see Appendix B)
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PBS
TMB+ Substrate (see Appendix B)
2N H2SO4  – Stop Solution
ELISA Wash buffer
 
Standards
The VEGF standard contained within the DuoSet kit, when reconstituted with 0.5 
ml of Reagent Diluent , was at a concentration of 120 ng/ml. This was diluted 
further to give aliquots at a concentration of 10,000 ρg/ml, which were stored in 
the freezer until required. Standards for each ELISA experiment were prepared 
not less than 15 minutes before the assay  was begun. Serial dilution of a 10,000 
ρg/ml aliquot with Reagent Diluent, was then used to create a standard curve. The 
concentrations on this curve were: 2000, 1000, 500, 250, 125, 62.5, 31.25 and 0 
ρg/ml. If a sample set had been previously assayed and shown VEGF values 
outside the 2,000 ρg/ml range, then further experiments were performed using a 
10,000 ρg/ml as the highest point on the standard curve.
Assay Procedure
On the first  day of the assay, 100 µl of Capture Antibody, diluted in PBS, was 
added to each of 96-wells on a Nunc ELISA plate. This plate was then covered, 
and left to incubate overnight at room temperature. 
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The following day, the plate was washed with ELISA wash buffer (Wash Buffer; 
see Appendix B). Each well on the plate was filled with Wash Buffer, dispensed 
by a squirt bottle. The plate was then inverted and tapped repeatedly, to remove all 
the Wash Buffer. This step  was repeated a further two times. After the final wash, 
the plate was inverted and blotted on a clean paper towel to remove all remaining 
liquid from the plate. The plate was then “blocked” by  adding 300 µl of Reagent 
Diluent, covering it and incubating it at  room temperature for a minimum of one 
hour.
Following this the plate was washed three times with Wash Buffer, as above. 100 
µl of sample or standard was then added to each well on the plate in duplicate. 
The origin of the samples was then recorded on a diagram showing the plate 
layout. When all the samples had been added, the plate was again covered, and 
incubated at room temperature for 2 hours. Next, the plate was washed three times 
with Wash Buffer, as above. 100 µl of Detection Antibody (see Appendix B) were 
then added to each well. The plate was covered and incubated at room 
temperature for 2 hours.
Next, the plate was washed three times with Wash Buffer. 100 µl of Streptavidin / 
HRP (see Appendix B) was added to each well. The plate was covered and 
incubated at room temperature for 20 minutes. The plate was then washed with 
Wash Buffer a further three times. 100 µl of Substrate Solution (TMB+; see 
Appendix B) was then added to each of the wells. The plate was covered and 
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incubated at room temperature for 20 minutes. Next, 50 µl of Stop Solution (2N 
H2SO4; see Appendix B) was added to each well. The plate was then gently 
tapped to mix the Stop Solution and the Substrate Solutions. 
Reading Absorbances
The optical density  of each well was determined using a microplate reader. 
(Spectra Max 190, Molecular Devices). Optical density was recorded at 450 nm, 
with wavelength correction set to 540 nm. A standard curve was created from the 
data-set using a 4 parameter logistic (4-PL) curve-fit. The software (Soft Max Pro, 
version 2.6.1, Molecular Devices) then calculated the amount of VEGF in each 
sample by comparing the optical density to that on the standard curve. 
Data Analysis and statistics
Graphing and data analysis and statistics were performed using GraphPad Prism 5 
for Mac. Data were statistically analysed using paired or unpaired Student’s t-test, 
and one-way  or two-way  ANOVA. P < 0.05 was considered significant. All data 
were reported as mean ± SEM.
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3RESULTS
3.1 Effects of Cobalt Chloride on VEGF Secretion in 
endometrial cancer cells
Cobalt Chloride (CoCl2) is routinely used as an experimental mimic of hypoxia 
(Dai et al., 2008; Shu et al., 2008). It interferes with the breakdown of HIF1-α, 
which leads to the transcription factor accumulating within the cell. This increase 
in HIF1-α results in an induction of the hypoxic response, as outlined in the 
previous section. CoCl2 induces the hypoxic response by preventing the 
breakdown of the HIF1-α molecule. CoCl2 competitively inhibits the PHD 
molecules, which hydroxylate HIF1-α under normoxic conditions. By preventing 
HIF1-α from becoming hydroxylated, CoCl2 stops HIF1-α from being broken 
down by VHL. This leads to the accumulation of HIF1-α, which then combines 
with HIF1-β, resulting in an increased level of the dimer. This leads to an up-
regulation of the genes which the HIF1 heterodimer modulates. In this project, we 
looked at the effect that two variables, duration and concentration of exposure to 
CoCl2, have on cell viability and VEGF production of endometrial cancer cells. 
The effects of the duration of CoCl2 exposure are presented in 3.1.1, while the 
effects of CoCl2 concentration are presented in 3.1.2. 
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3.1.1 Effect of Duration of CoCl2 Treatment on VEGF Release from RL952 
cells
The length of time the cells are exposed to CoCl2 is an important factor in the 
subsequent expression of VEGF. Studies reported in the literature, together with 
prior studies on endometrial cancer from this laboratory, have incubated cells with 
CoCl2 for 24 hours. A 100 µM concentration of CoCl2 was incubated for 24 hours 
to induce VEGF expression in cultured cancer cells (Dai et al., 2008). To confirm 
the robustness of this protocol, a preliminary  experiment was undertaken to 
establish a pattern of VEGF expression. An exposure time was then selected to be 
used for all subsequent experiments.
Initial experiments were undertaken in the endometrial adenocarcinoma cell line 
RL952. Cells were grown to confluence in a 175 cm2 flask, then split into a 24 
well plate, following the protocol outlined in the methods section. Cells were then 
incubated with 100 µM  of CoCl2 for the duration indicated. Four wells were 
incubated with CoCl2 for the time indicated. The supernatant from each set of 
samples was collected from the plate and immediately frozen. 
It was found that the amount of VEGF in the supernatant of RL952 cells, 
measured by VEGF ELISA, did not change significantly  during the first  6 hours 
of incubation (Figure 3.1.1). Between the 6 and 12 hour time points there was a 
dramatic increase in the amount of VEGF found in the supernatant. This response 
was observed to continue to increase over the next  12 hours. The response at 24 
hours was roughly double that at 12 hours. The variation in VEGF levels, as 
represented by the standard deviation of each data point  on the graph, was much 
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larger at the 12 hour time point than at the 24 hour time point. As the 24 hour time 
of incubation with CoCl2 caused a significant increase in VEGF activity, and with 
less variability than the 12 hour incubation, 24 hour incubations were used in all 
subsequent assays.
3.1.2 Effect of concentration of CoCl2 exposure on VEGF release from 
RL952 Cells
Whilst CoCl2 is a potent mimic of hypoxia, and elicits VEGF secretion, it can also 
have cytotoxic effects on the cell. Experiments were undertaken, first in the 
immortalised endometrial cancer cell line, RL952, followed with experiments 
using primary  cultured endometrial cancer cells, to find a dose of CoCl2 that 
increased VEGF release without having an excessively cytotoxic effect on cells. 
Levels of VEGF secretion were measured by ELISA of supernatant from cultured 
cells. The viability of the cells was determined using the MTT assay of cell 
viability. Initial experiments were undertaken in the endometrial adenocarcinoma 
cell line RL952. Cells were grown to confluence in a 175 cm2 flask, then split into 
a 24 well plate, following the protocol outlined in the methods section. Cells were 
then incubated with concentrations of CoCl2, from 0 µM   to 1600 µM. Four wells 
were incubated for each concentration indicated. After 24 hours, the supernatant 
from each set of samples was collected from the plate and immediately frozen.
In RL952 cells, the level of VEGF was increased markedly by 100 µM  CoCl2 
dose. The highest level of secretion was attained at  400 µM CoCl2, and above this 
dose the levels declined. The variation in VEGF secretion in response to 100 µM 
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Figure 3.1.1 VEGF levels in the supernatant in response to duration of exposure to CoCl2. RL952 
endometrial cancer cells were incubated with 100 µM of CoCl2 for the times indicated. 
Supernatants were removed from the cells at these points. Data is plotted as mean of 4 samples ± 
SEM. 
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Figure 3.1.2a VEGF levels in supernatant in response to concentration of CoCl2. RL952 
endometrial cancer cells were incubated with CoCl2 at the concentrations shown for 24 hours. 
Supernatants were removed from the cells at this point. Data is plotted as mean of 4 wells ± SEM.
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CoCl2 was relatively large, however the graph (figure 3.1.2.a) depicts the results 
of a small number of samples. The effect of 100 µM  CoCl2 on the viability of the 
cells was measured using the MTT test. Higher absorbance values showed that the 
cells were converting more of the MTT into the coloured product that was 
measured in the assay. A higher absorbance indicates more active cells in the well, 
and thus higher viability. As can be seen in figure 3.1.2.b, the mean absorbance of 
the groups of cells exposed to CoCl2 is significantly lower than the control group 
(p<0.0001, n=6), showing that at 100 µM CoCl2 increases the level of VEGF in 
cultured RL952 endometrial cancer cells, whilst also having a small but 
significant negative effect on the viability these cells.
3.1.3 Effect of CoCl2 concentration on VEGF release from Endometrial 
Cancer Cells
The effects of CoCl2 on VEGF and cell viability  that were seen in RL952 cells 
were also seen in primary cultured cells. The basal VEGF levels in the cultured 
primary endometrial cancer cells were lower than that of the the RL952 cells. This 
occurred consistently throughout the subsequent experiments, with the 
immortalised cell line showing higher activity  when compared to the primary 
cells. This was not unexpected, as the RL952 cells had been specifically selected 
to be a fast growing, robust cancer cell line. The cultured primary tissues, 
however, are samples from patients, which had been randomly selected, not 
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Figure 3.1.2b Cell Viability in RL952 Endometrial Cancer Cells when exposed to 100 µM CoCl2 
for 24 hours. Cell viability of adherent cells was measure using the MTT assay. After supernatant 
had been removed, MTT was added and cells left to incubate as described in methods section 
2.3.1. Data is plotted as mean of 15 samples ± SEM. 
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selected for on the basis of the rate at which they grow or express certain 
molecules. 
Concentrations of CoCl2 less than 100 µM did not appear to significantly increase 
the amount of VEGF released (figure 3.1.3a). 200 µM increased VEGF levels 
further than 100 µM, but with a larger standard deviation. The 400 µM  dose did 
not increase VEGF any more than 200 µM, which suggesting a maximum effect. 
As figure 3.1.3b shows, 100 µM CoCl2 would appear to reduce the MTT product 
formed by cultured primary cells.  This shows that a 100 µM  dose of CoCl2 
increased the level of VEGF released from cultured primary endometrial cancer 
cells, whilst also having a small but significant negative effect on the viability 
these cells.
A CoCl2 concentration of 100 µM incubated for 24 hours resulted in an increase 
in VEGF in both RL952 and primary endometrial cancer cells. This increase is 
considered to reflect the ability of CoCl2 to accurately mimic an effect of hypoxia. 
Though this dose of CoCl2 would appear to result in a small but significant 
decrease in the viability  of the cultured cells, the magnitude of the change is such 
that the system can still be considered a viable model in which to study the effects 
of HIF1-α during hypoxia. As both the 100 µM concentration of CoCl2 and the 24 
hour incubation time are routinely used in examples in the literature, these two 
variables were fixed for the remainder of experiments.
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Figure 3.1.3a VEGF levels in primary endometrial cancer cells when exposed to CoCl2. VEGF 
level was measured using ELISA. Cells were incubated with the relevant dose of CoCl2 for 24 
hours. Supernatants were removed from the cells at this point.  Data is plotted as mean of n 
samples ± SD
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Figure 3.1.3b Cell Viability in Primary Endometrial Cancer Cells when exposed to CoCl2. Cell 
viability of adherent cells was measure using the MTT  assay. After supernatant had been removed, 
MTT was added and cells left to incubate. Data is plotted as mean of n samples ± SD
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3.2 Effects of Resveratrol on VEGF Release from in 
Endometrial Cancer Cells
3.2.1 Effects of Resveratrol Concentration on Cell Viability
The viability  of cells in the presence of resveratrol is an important consideration 
in determining the utility  of the substance. Experiments were undertaken on both 
RL952 and primary cultures of tumour cells. Resveratrol was added to the cells at 
a concentration of 100 µM, and cells were incubated for 24 hours. The 
supernatant was then collected for VEGF assay  (see section 3.2.3), and also an 
MTT assay was performed on the adhesive cells. When performed on RL952 cells 
(Figure 3.2.1a), the MTT assay revealed that the absorbance of the cells treated 
with resveratrol was significantly lower than those without (mean (0 µM) =1.147 
± 0.04; mean (100 µM) = 0.929 ± 0.038). A similar decrease in viability was seen 
in primary cultures (figure 3.2.1b). Three doses of resveratrol were used in this 
assay (Figure 3.2.1b). 50 µM resveratrol was seen to reduce the viability  by 
approximately the same amount as 100 µM but the viability levels were not 
significantly different from control incubations. 200 µM  appears to reduce the 
viability further, giving an absorbance value that is significantly less than the 
control.
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Figure 3.2.1a Cell Viability in RL952 Endometrial Cancer Cells when exposed to resveratrol. Cell 
viability of adherent cells was measured using the MTT assay.  Cells were exposed to either 0 µM 
resveratrol or 100 µM resveratrol. After supernatant had been removed, MTT was added and cells 
left to incubate. Data is plotted as mean of 6 samples ± SEM
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Figure 3.2.1b Cell Viability in primary endometrial cancer cells when exposed to resveratrol.  Cell 
viability of adherent cells was measure using the MTT assay. Cells were exposed to a dose of 
resveratrol as indicated on the X axis. After supernatant had been removed, MTT was added and 
cells left to incubate. Data is plotted as mean of 15 samples ± SEM
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3.2.2 Effects of Resveratrol in combination with CoCl2 on cell viability
As a key aim of this research was to investigate whether resveratrol inhibits the 
effect of hypoxia in endometrial cancer cells,  the effect it has on cell viability 
when combined with CoCl2 is relevant. As both resveratrol and CoCl2 have 
negative effects on the viability of cultured cells, the aim of these experiments 
was to investigate whether the two substances in combination had an additive 
effect on the viability of cells. 
As was seen in the prior experiment, 100 µM CoCl2 and 100 µM resveratrol both 
significantly reduced the viability of cells when used separately. When given 
together as a treatment in RL952 cells, a reduction in viability was not observed 
(Figure 3.2.2a). Cells with 0 µM resveratrol plus 100 CoCl2 or 100 µM  resveratrol 
plus 0 µM  CoCl2 had comparable levels of cell viability. There was no significant 
decrease in viability in cells which were exposed to 100 µM resveratrol plus 100 
µM CoCl2. This suggests that 100 µM resveratrol plus 100 µM CoCl2 in 
combination have less effect on cell viability than resveratrol or CoCl2 in 
isolation. 
The pattern shown in RL952 cells was again seen with primary endometrial 
cancer cells. Figure 3.2.2b shows cells exposed to four doses of resveratrol (0 µM, 
50 µM, 100 µM, 200 µM) with or without the presence of CoCl2. While CoCl2 
reduces cell viability when given to cells without resveratrol, there was an 
increase in the viability when the two agents were added together. As this effect is 
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Cell Viability in RL952 Cells when exposed to various 
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Figure 3.2.2a Cell Viability in RL952 cells when exposed to resveratrol and CoCl2. Cell viability 
of adherent cells was measure using the MTT  assay. Cells were exposed to a dose of resveratrol as 
indicated on the X axis. + and - indicates whether the cells were incubated with CoCl2 (+) or 
without CoCl2 (-). After supernatant had been removed,  MTT was added and product was 
measured as described in methods. Data is plotted as mean of 6 samples ± SEM 
Cell Viability of Primary Endometrial Cancer Cells when exposed to 
Resveratrol and CoCl2
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Figure 3.2.2b Cell Viability in primary endometrial cancer cells when exposed to resveratrol and 
CoCl2. Cell viability of adherent cells was measure using the MTT assay. Cells were exposed to a 
dose of resveratrol as indicated on the X axis. + and - indicates whether the cells were incubated 
with CoCl2 (+) or without CoCl2. After supernatant had been removed, MTT was added and 
product was measured as described in methods. Data is plotted as mean of 15 samples ± SD
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seen across both RL952 and primary  cultured cells, it can be concluded that whilst 
resveratrol and CoCl2 each have negative effects on cell viability, the combination 
of the two results in nonsignificant decrease in cell viability. Given this result, any 
effects which resveratrol may have on reducing VEGF levels in the presence of 
CoCl2 cannot be attributed to the substance having a cytotoxic effect on the cells. 
3.2.3 Effects of Resveratrol on VEGF Levels
The effect of resveratrol on VEGF Expression was investigated. It was 
hypothesised that adding resveratrol to cultured endometrial cancer cells would 
lead to a reduction in VEGF released. VEGF is a readily assayed marker of 
angiogenic stimulation. As was shown in the previous sections, CoCl2 increased 
the expression of VEGF, and can thus be considered a hypoxia mimic. Since 
angiogenesis is induced by  increased levels of HIF1-α, the aim of the following 
experiments was to investigate whether resveratrol could reduce the hypoxic-like 
behaviour of cells occurring as a consequence of the effects of CoCl2. This 
hypothesis was tested in both RL952 immortalised cells and primary  endometrial 
cancer cell cultures.
RL952 Endometrial Cell Line
The effects of resveratrol 100 µM on basal and CoCl2-stimulated VEGF release 
were measured in RL952 cells. RL952 cells were grown on 24 well culture plates, 
and incubated in the presence or absence of resveratrol or CoCl2; control, CoCl2 
only, resveratrol only and resveratrol with CoCl2. In the absence of resveratrol, 
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Change in VEGF Levels of RL952 Cells 
Exposed to Resveratrol and CoCl2
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Figure 3.2.3a VEGF levels supernatant of primary endometrial cancer cells after exposure to 
resveratrol and CoCl2. VEGF Level was measured using ELISA. Cells were incubated with the 
relevant concentration of CoCl2 for 24 hours.  Cells were exposed to a dose of resveratrol as 
indicated on the X axis. + and - indicates whether the cells were incubated in the presence of 
CoCl2 (+) or  in the absence CoCl2 (-). Supernatants were removed from the cells at this point. 
Data is plotted as mean of 26 samples ± SEM 
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CoCl2 caused a significant increase in the amount of VEGF released (figure 
3.2.3a). This would suggest that the hypoxic effect of CoCl2 leads to an increase 
in the amount of VEGF in the supernatant of cells. The level of VEGF released by 
cells incubated with resveratrol alone was significantly lower than the control 
treatment. (p<0.0001, n=15, paired t-test), indicating that resveratrol reduces 
VEGF secretion. When resveratrol and CoCl2 were combined, the mean VEGF 
level was not significantly different from the control group (36050 ρg/ml and 
33602 ρg/ml respectively, n=15, NS, paired t-test). It was, however, significantly 
less than the VEGF release seen with the CoCl2 only treatment (p<0.0006, n=15, 
paired t-test), indicating that resveratrol significantly reduced the hypoxic effect 
of CoCl2 on RL952 cells. 
Primary endometrial tumour cells
The effects of resveratrol 100 µM on basal and CoCl2-stimulated VEGF release 
were measured in primary endometrial cancer cells. The treatments were as 
described above for RL952 cells. The cells used were from 19 primary tumours 
that were collected and grown as cell cultures, as indicated in the methods section. 
CoCl2 caused an increase in VEGF levels (figure 3.2.3b.A) that was significantly 
above that of the control treatment (mean (control)= 350.4 ρg/ml ± 57.46 cf mean 
(CoCl2)= 926.3 ρg/ml ± 125.4, n=108, P<0.0001, paired t-test). The increase gave 
a VEGF level that was well over double that of the control. The second graph 
(figure 3.2.3b.B) showed that resveratrol significantly  reduced VEGF to 120.6 ρg/
ml ± 30.3 (n=113, p<0.0001, t-test)
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In the third graph (figure 3.2.3b.C), CoCl2 was compared to resveratrol plus 
CoCl2. Though the mean of the resveratrol and CoCl2 was lower (mean = 245.6 
ρg/ml ± 45.45) than that of the control (mean= 350.4 ρg/ml ± 57.46), this 
difference was not significant (n=111, NS, t-test). Though the resveratrol and 
CoCl2 group could not be shown to be statistically  lower than the control, this 
could be interpreted as the resveratrol and CoCl2 group being the same as the 
control. This shows that the resveratrol treatment reversed the effect of HIF1-α 
increase induced by CoCl2. 
The fourth graph (figure 3.2.3b.D) compared the 0 µM resveratrol plus 100 µM 
CoCl2 group  to the 100 µM resveratrol plus 100 µM CoCl2 group. The mean 
VEGF level of the resveratrol plus CoCl2 group (mean = 245.6 ρg/ml ± 45.45) 
was significantly  lower (n=111, p<0.0001, t-test) than that of the CoCl2 group 
(mean = 926.3 ρg/ml ± 125.4). These results support those described in RL952 
cells earlier in this section, and suggest that the pattern of VEGF response to 
CoCl2 and resveratrol in both endometrial cancer cell lines and primary cultured 
endometrial cells is robust. These results are collated in the table below.
Treatment 0 µM Resveratrol 100 µM
Resveratrol
0 µM CoCl2
100 µM CoCl2
350.4 ρg/ml ± 57.46 120.6 ρg/ml ± 30.3
926.3 ρg/ml ± 125.4 245.6 ρg/ml ± 45.45
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VEGF Levels in Endometrial Cancer Cells exposed to 
Resveratrol and CoCl2
Figure 3.2.3b VEGF levels supernatant of Primary Endometrial Cancer Cells after exposure to 
resveratrol and CoCl2. VEGF Level was measured using ELISA. Cells were incubated with the relevant 
treatment for 24 hours.  Supernatants were removed from the cells at this point. (A) shows mean VEGF 
from control group (350.4 ρg/ml ± 57.46) is less than mean VEGF from CoCl2 group (926.3 ρg/ml ± 
125.4) (n=108, P<0.0001, paired t-test). (B) shows that the mean of the resveratrol 100 group (120.6 ρg/
ml ± 30.3) is less than the control (n=113, p<0.0001, t-test). (C) shows mean VEGF from resveratrol + 
CoCl2 group (245.6 ρg/ml ± 45.45 ) is less than the mean VEGF from control group (350.4 ρg/ml ± 
57.46), however this does not reach significance (n=111, NS, t-test) (D) shows mean VEGF from 
resveratrol + CoCl2 group (245.6 ρg/ml ± 45.45 ) is significantly less than mean VEGF from CoCl2 group 
(926.3 ρg/ml ± 125.4) (n=111, p<0.0001, t-test) Data is plotted as mean of samples ± SEM
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3.3 Effect of EGCG on VEGF release from in endometrial 
cancer cells
The effects of EGCG on VEGF levels in endometrial cancer cells in basal culture 
conditions and when HIF1-α levels are increased by CoCl2 was examined. The 
experimental procedure used was identical to that used to test the effects of 
resveratrol on VEGF levels, except that EGCG was substituted for resveratrol. 
Primary  endometrial cancer cells were grown up to confluence, then transferred 
into 24 well plates. The cells were then incubated with the treatment agent for 24 
hours, before the supernatant was collected for assay.
3.3.1 Effect of EGCG on VEGF Levels
As was seen in previous experiments, 100 µM CoCl2 (figure 3.3.1b.A) caused an 
increase in the amount of VEGF in the supernatant (mean=537.65 ρg/ml ± 70.26) 
when compared to the control (436.06 ρg/ml ± 86.74). However, unlike the 
previous graphs, this result  is not significant (n=22, NS, t-test), possibly due to 
smaller sample size in this experiment (n=22), giving larger standard error.
Figure 3.3.1b.B showed that EGCG strongly inhibited VEGF levels. Cells were 
treated with 100 µM  of EGCG. This led to a significant reduction in the amount 
of VEGF found in the supernatant  (82.39 ρg/ml ± 19.54). This was approximately 
one fifth of the level of VEGF seen in the control group. The difference between 
the two means was statistically significant (n= 22, p<0.0001, t-test). 
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The next figure (figure 3.3.1b.C) shows that 100 µM EGCG plus 100 µM  CoCl2 
reduces VEGF, though not to the same degree as 100 µM  EGCG only. The mean 
VEGF level of the supernatant from cells incubated with 100 µM EGCG plus 100 
µM CoCl2 was 235.65 ρg/ml ± 47.42. This was significantly  lower than the VEGF 
level of the Control (n=22, P=0.0315, t-test). The final graph (figure 3.3.1b.D) 
compares the CoCl2 only group with the 100 µM EGCG plus 100 µM CoCl2 
group. The difference between the two means was statistically significant 
(p<0.0001, n=36, t-test), with the 100 µM  EGCG plus 100 µM  CoCl2 treatment 
having a mean VEGF level of less than half the CoCl2 only  group. This showed 
that EGCG was a potent inhibitor of VEGF secretion from endometrial cancer 
cells, and significantly  reduced the effects of CoCl2. The results are summarised 
in the following table. 
Treatment 0 µM EGCG 100 µM EGCG
0 µM CoCl2
100 µM CoCl2
436.06 ρg/ml ± 86.74 82.39 ρg/ml ± 19.54
537.65 ρg/ml ± 70.26 235.65 ρg/ml ± 47.42
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Change in VEGF Levels in Endometrial Cancer Cells 
exposed to EGCG Treatments
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Figure 3.3.1b VEGF levels supernatant of Primary Endometrial Cancer Cells after exposure to EGCG 
and CoCl2. VEGF Level was measured using ELISA. Cells were incubated with the relevant treatment for 
24 hours.  Supernatants were removed from the cells at this point. (A) shows mean VEGF from control 
group (436.06 ρg/ml ± 86.74) is less than mean VEGF from CoCl2 group (mean=537.65 ρg/ml ± 70.26) 
(n=22, NS, t-test) (B) shows that the mean of the EGCG 100 group (82.39 ρg/ml ± 19.54) is less than the 
control (n= ?,  p<0.0001, t-test). (C) shows mean VEGF from EGCG + CoCl2 group (235.65 ρg/ml ± 
47.42) is significantly less than the mean VEGF from control group (350.4 ρg/ml ± 57.46) (n=?, 
P=0.0315, t-test). (D) shows mean VEGF from EGCG + CoCl2 group (235.65 ρg/ml ± 47.42) is 
significantly less than mean VEGF from CoCl2 group (537.65 ρg/ml ± 70.26) (p<0.0001,  n=36, t-test) 
Data is plotted as mean of n samples ± SD
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3.4 Immunohistochemistry
Immunological staining of endometrial cancer cells used in experimental work 
was undertaken to establish the type of cells that were experimented on. Cells 
were fixed and stained by the Pathology Department, Christchurch Hospital. 
Staining solutions were selected to identify whether cells were endometrial 
epithelial or endometrial stromal cells. These solutions were stains that were 
either cytokeratin or vimentin specific. At least 50% of cells stained positive for 
cyotkeratin, whilst less than 10% stained positive for vimentin. This staining 
shows that most of the cultured cells are stromal cells. Two further stains were 
then used, CD10 and CD31. CD31, which stains for endothelial cells, was 
negative in the cultured cells. CD10, which stains for stromal cells, was positive. 
This staining confirmed that the cells grown and experimented upon were 
predominantly endometrial stromal cells. It was expected that most of the cells 
would have been epithelial cells, as they are cells in which endometrial 
adenocarcinomas develop. When the tumour was post-operatively dissected by the 
pathologist, a section of epithelial cells was provided. However, stromal cells 
appear to grow more readily  than epithelial cells using the cell culture methods 
utilised in this project.
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4DISCUSSION
4.1 Effect of CoCl2 on VEGF release from endometrial 
cancer cells
This study  shows that  endometrial cancer cells incubated in the presence of 
CoCl2 released significantly  larger amounts of VEGF than cells that were 
incubated without CoCl2. As increased VEGF is a major angiogenic factor in 
endometrial cancers (Sivridis et al., 2002), endometrial cancer cells incubated 
with CoCl2 can be considered as an in vitro model for cells undergoing 
angiogenesis. Based on previous literature that has used the same concentrations 
of CoCl2 (Dai et al., 2008; Shu et al., 2008), it is assumed that CoCl2 is working 
by inducing HIF1-α expression and therefore acting as a hypoxia mimic.
The results of the immunohistochemistry tests identified that the majority  of cells 
cultured cells in this project were endometrial stromal cells. As the cells that were 
initially cultured were from the epithelial layer of the tumour, it was expected that 
the cultured cells would also be epithelial cells. However, cell dispersion and 
repeat passages of the cells may have selected out stromal cells from sample. As 
the stromal cells appear to grow better in these conditions that epithelial cells, the 
ratio of stromal to epithelial cells being cultured moves toward the former. 
Previous work in this laboratory has shown that CoCl2 can trigger an increase in 
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the amount of VEGF released from endometrial stromal cells (Abbas et al., 2004), 
which supports the patterns of VEGF release reported in this thesis.
4.2 Effect of Resveratrol on VEGF release from 
endometrial cancer cells
Resveratrol has been used previously in endometrial cancer cells, however this 
project is the first to have investigated the effects of resveratrol on VEGF levels in 
this system. It had previously been shown that  resveratrol exerted a tumouricidal 
effect in uterine cancer cells (Sexton et al., 2006), including endometrial cancer 
cell lines RL952 and Ishikawa, which were both used in this study. However, the 
focus of this study was apoptosis, rather than angiogenesis, and studied the COX 
molecule. Similarly, resveratrol was used in a study  which looked at cytostatic and 
anti-estrogenic markers in the Ishikawa endometrial adenocarcinoma cell line 
(Bhat and Pezzuto, 2001), but concluded that it had little effect on these markers. 
The dose used in the study (10 µm) was much lower than used in this work. This 
study was the first to show that resveratrol reduces the secretion of VEGF in 
endometrial cancer cells. By using resveratrol at a concentration of 100 µm, the 
amount of VEGF released into the supernatant of endometrial cancer cells was 
significantly reduced, when compared to the VEGF levels in the supernatant of 
endometrial cancer cells without  treatment. When compared to cells with had 
increased VEGF release induced by CoCl2, resveratrol again significantly reduced 
the amount of VEGF in the supernatant. This suggests that resveratrol can reduce 
the angiogenic effects induced by hypoxia in endometrial cancer cells. This 
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supports research previously published that has investigated the effect of 
resveratrol on VEGF and HIF1-α in other tumour types. 
While this study did not measure cellular HIF1-α levels directly, studies reported 
in the literature suggest that  resveratrol reduces VEGF by inhibiting HIF1-α. 
Increased levels of VEGF and HIF1-α are found in ovarian cancer (Wong et al., 
2003) and resveratrol has been shown to inhibit HIF1-α and reduce VEGF levels 
in this cancer (Cao et al., 2004). As VEGF has been shown to correlate with HIF 
expression in endometrial cancers (Ozbudak et al., 2008), it  would be expected 
that inhibition of HIF1-α by resveratrol would appear to be the mechanism by 
which the compound reduces VEGF levels. However, direct measurement of 
HIF1-α levels in endometrial cancer cells treated with resveratrol is still required 
to confirm this.
Studies that have investigated the role of VEGF in endometrial cancer have shown 
that the level of VEGF and HIF1-α was significantly elevated in these cancers 
(Kazi and Koos, 2007). A large study that looked at rates of breast cancer - 
another cancer that shows elevated HIF levels (Kimbro and Simons, 2006) - found 
that women who consumed more resveratrol in their diets had lower risks of 
developing breast  cancer (La Vecchia and Bosetti, 2006). Given the significant 
reductions in VEGF caused by resveratrol in this study, further investigation into 
the effects of dietary resveratrol on endometrial cancer rates are warranted. 
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4.3 Effect of EGCG on VEGF release from endometrial 
cancer cells
This study was the first to show that EGCG, a catechin extract from green tea, 
reduces the secretion of VEGF in endometrial cancer cells. By using EGCG at a 
concentration of 100 µm, the amount of VEGF released into the supernatant of 
endometrial cancer cells was significantly reduced, when compared to the VEGF 
levels in the supernatant  of endometrial cancer cells without treatment. When 
compared to cells with had increased VEGF release induced by  CoCl2, EGCG 
again significantly reduced the amount of VEGF in the supernatant. This suggests 
that EGCG can reduce the angiogenic effects induced by  hypoxia in endometrial 
cancer cells. This result is supported from other worked previously reported that 
has investigated the effects of EGCG on VEGF release in other cancer cell types, 
including cervical and hepatoma cells (Zhang et  al., 2006). However, replication 
of this result is required, as it has been reported that EGCG can actually lead to an 
increase in VEGF (Thomas and Kim, 2005) and in cell proliferation (Zhou et al., 
2004).
As seen in figure 3.1.1.b, the Cocl2 group was not significantly  higher than the 
control group, though it was significantly higher in the resveratrol experiments. 
This is possibly due to smaller sample size in this experiment (n=22), giving 
larger standard deviation. It could also be attributed, in part, to primary tumours 
used in this experiment rather than a cell line. As fewer tumours were used than in 
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the resveratrol study, a disproportionate number of tumours that express low 
levels of VEGF may be represented in this graph. Further investigation into the 
effects of EGCG on VEGF levels in cancer cells should be undertaken before it 
can be recommended that green tea be considered as an anti-cancer agent.
4.4 Suggestions for further research
Though it has been shown that resveratrol and EGCG reduce VEGF, the effects of 
these substances on the expression of HIF1-α have not been measured directly. An 
investigation into the effects of these food compounds on HIF1-α protein levels, 
as well as mRNA levels would contribute to our better understanding of the role 
with HIF1-α and VEGF have in endometrial cancers. It would also be interesting 
to see whether there is a correlation between HIF1-α expression and VEGF levels 
in cultured cancer cells, and if, as we expect, there is, whether the changes in 
VEGF that are seen with CoCl2, resveratrol and EGCG can be primarily attributed 
to HIF1-α, or whether there is another factor involved that effects VEGF in these 
situations. Another area of interest would be investigating the level of basal HIF1-
α expression in primary endometrial tumours, to see whether this was correlated 
with grade. Many of the tumour that have higher basal levels of VEGF secretion 
have a less dramatic response to CoCl2 than tumours that have lower levels of 
basal VEGF. It  would be interesting to investigate whether this differential 
response was related to basal HIF1-α levels, as it may be that tumours with higher 
basal HIF1-α are less affected than tumours with lower basal levels. HIF1-α 
protein expression could be measured by Western Blotting, or HIF1-α ELISA. The 
mRNA levels of HIF1-α could be investigated using Real-Time Polymerase Chain 
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Reaction (RT-PCR). Interfering with the HIF1-α gene with small interfering RNA 
(si-RNA) could be performed to see what the levels of VEGF secreted by  the cell 
were when there was little or not active HIF1-α inducing expression. By 
combining these techniques with the results of this paper and work completed 
previously  in the literature, we could construct a more complete picture of the role 
of HIF1-α and VEGF in the hypoxic response of endometrial cancer cells.
While this research has shown that resveratrol is a strong inhibitor of VEGF 
secretion in endometrial cancer cells, there may be other compounds in grapes or 
red wine that have anti-angiogenic activity. Experiments similar to the ones 
performed in this study could be undertaken, to investigate whether less processed 
fractions of grape skin extract have similar effects on VEGF and HIF in 
endometrial cancer. It has been shown that resveratrol and an extract of grape skin 
act to inhibit prostate cancer growth, but that the two substances act through 
distinct pathways (Hudson et al., 2007). Further work on the effects of resveratrol 
and other extracts of grape skin will be necessary for any consideration of red 
wines as anti-cancer dietary supplements. It would also be interesting to 
investigate whether there was a syngeristic effect on VEGF levels when 
resveratrol and EGCG were combined, as has been suggested (Morre and Morre, 
2006; Sagar et al., 2006a, b). 
While some papers investigating links between mutations in the HIf gene and 
cancer have failed to establish a link (Apaydin et al., 2008; Kuwai et al., 2004), a 
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recent paper (Konac et  al., 2007) showed that women with mutations in their 
HIF1-α genes had an increased risk of developing gynaecologic cancers, including 
endometrial cancer. Using the endometrial cancer samples collected during this 
study, and those stored in the cancer society  tissue bank, gene sequencing could 
be undertaken to establish whether this pattern was observable in a group of New 
Zealand women. Basal VEGF expression from the samples could be matched with 
the gene sequence, to establish whether the amount of VEGF secreted by cultured 
endometrial cancer cells was directly related to mutation status of the HIF1-α 
gene. Further to this, mutations in the HIF1-α gene could then be cross referenced 
with tumour grade to investigate whether there is a correlation between the two. 
HIF1-α gene sequence information could also be used to investigate the 
pharmacogenetic properties of Resveratrol and EGCG. A number of recent  papers 
have looked at the relationship between genes and environmental factors in 
determining a response to a stimulus (Caspi et al., 2002; Caspi et al., 2003). It 
would be interesting to investigate whether a tumours response to Resveratrol or 
EGCG was a function of the mutation state of its HIF1-α gene. The effect of the 
food compounds on VEGF levels may be affected by whether the specific tumour 
carries a mutation in the HIF1-α gene. 
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APPENDICES
SOLUTIONS
1. Cell Culture
Phosphate Buffered Saline (PBS) 10X
The solution was made up by dissolving the following reagents in milliQ H2O. 
The total volume was 1L, and the concentration was 10X that which was 
generally  used in experimental work. After all reagents had been completely 
dissolved, the pH was adjusted to 7.4 using concentrated NaOH or HCl. The 
concentrated PBS was then stored at room temperature. 
NaCl      80.0g
Na2HPO4     11.5g
KCl      2.0g
KH2PO4      2.0g
MilliQ H20     1L
Collagenase Dissolving Buffer
The first six reagents were added together, and dissolved in the MilliQ H2O. Once 
dissolved, glucose and sodium bicarbonate were added. Once dissolved, 
CaCl2.2H20 was added. 5.0 ml of Penicillin Streptomycin was then added and the 
pH of the solution was adjusted to 7.4 using concentrated NaOH or HCl. The 
solution was then passed through a 0.22 µm filter (millexGP) into a sterile bottle, 
and stored at 4°C. 
NaCl      4.0g
KCl      0.2g
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Na2HPO4     0.19g 
KH2PO4      0.03g
MgSO4.7H2O     0.05g
MgCl2.6H2O     0.05g
MilliQ H20     495 ml
 Then
Glucose      0.5g
NaHCO3     0.175g
CaCl2.2H20     0.092g
Penicillin / Streptomycin   5.0 ml
Collagenase Solution
The collagenase was added to the dissolving buffer, and well mixed. Then, under 
aseptic conditions, the solution was passed through a 0.22 µm filter (millexGP) 
into 50 ml Falcon tubes. These were then stored at 4°C.
Collagenase Type 1A    100 mg
Collagenase dissolving buffer   50 ml
α-Minimum Essential Medium  Medium (α-MEM)
950 ml of milliQ water was measured out into a 1L Schott  bottle that  had been 
washed and autoclaved. To this, the powdered medium was added. MilliQ water 
was then used to rinse the packet, and remove any remaining traces of medium 
powder. NaHCO3 was then added, and Penicillin Streptomycin and fungizone 
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added. Solution was next made with to 1 litre with MilliQ water. Solution was 
then stirred with a magnetic stirring bar. pH of the solution was adjusted to 7.4 
using concentrated NaOH or HCl, added slowly with stirring. Solution was then 
filtered into another sterile, autoclaved 1l Schott  bottle using a vacuum filter 
(Vacucap  0.2 µm). This was done under aseptic conditions in the cell culture 
hood. α-MEM was stored at 4°C until required.
Minimum Essential Medium α Medium 1 Packet
NaHCO3     2.2g
Penicillin Streptomycin   10.0 ml
Fungizone     4.0 ml
MilliQ H20     1L
Phenol-Red Free Minimum Essential Medium (PRF-MEM)
950ml of milliQ water was measured out into a 1L Schott bottle that had been 
washed and autoclaved. To this, the powdered medium was added. MilliQ water 
was then used to rinse the packet, and remove any remaining traces of medium 
powder. NaHCO3, L-Glutamine, Penicillin Streptomycin and fungizone were 
added. Solution was next made with to 1 litre with MilliQ water. Solution was 
then stirred with a magnetic stirring bar. pH of the solution was adjusted to 7.4 
using concentrated NaOH or HCl, added slowly with stirring. Solution was then 
filtered into another sterile, autoclaved 1l Schott  bottle using a vacuum filter 
(Vacucap  0.2 µm). This was done under aseptic conditions in the cell culture 
hood. PRF-MEM was stored at 4°C until required.
Minimum Essential Medium Eagle  1 Packet
NaHCO3     2.2g
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Penicillin Streptomycin   10.0 ml
Fungizone     4.0 ml
L-Glutamine     0.292g
MilliQ H20     1L
Fungizone
Fungizone (Amphotericin B 250g/ml)  4.0 ml
Stored in freezer at -18°C until required. 
2. Experimental Treatments
Resveratrol Stock Solution
DMSO was added to the resveratrol container. The container was then vortexed 
until all the powder was in solution. The solution was then transferred to a 50 ml 
Falcon tube and stored in the freezer at -18°C until required. The concentration of 
this stock solution was 10,000 µg/ml. 
Resveratrol     100 mg
DMSO      43.8212 ml
CoCl2 Stock Solution
CoCl2 powder was measured out, and added to sterile bottle. MilliQ H2O then 
added and solution was mixed until all powder was dissolved. Filtered through 
0.22 µm filter (millexGP) into 15 ml Falcon tubes. Stored at 4°C. Stock at 20,000 
µg/ml
CoCl2      237.93 mg
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MilliQ H2O     50 ml
EGCG Stock Solution
EGCG      50 mg
MilliQ H2O     10.91 ml
EGCG powder was measured out, and added to sterile bottle. MilliQ H2O then 
added and solution was mixed until all powder was dissolved. Filtered through 
0.22 µm filter (millexGP) into a 15 ml Falcon tube. Stored at at -18°C. Stock at 
20,000 µg/ml
3. ELISA Reagents
ELISA Wash Buffer
TWEEN and 10X PBS were added to a 1l Schott  bottle. Solution was made up to 
1l with MilliQ H2O.
PBS 10X     100 ml
TWEEN 20     0.5 ml
MilliQ H20     900 ml
Reagent Diluent
BSA was added to sterile bottle with PBS. Solution was stirred using a magnetic 
stirrer until BSA completely dissolved. The solution was then filtered using a 0.22 
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µm filter (millexGP) into 50 ml Falcon tubes. Solution was stored at 4°C until 
required.
BSA      1g
PBS      100 ml
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